(SeaPRwire) – MAINZ, Germany, April 21, 2026 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) is set to disclose its first-quarter 2026 financial results on Tuesday, May 5, 2026. In addition, the Company will hold a conference call and webcast the same day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts, and the general public to review its financial results and share a corporate update.
To join the live conference call by phone, please register using this link. After registration, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and webcast audio will be accessible via this link.
Attendees can also access the slides and conference call webcast through the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call ends and archived on the Company’s website for 30 days following the event.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next-generation immunotherapy company pioneering innovative experimental therapies for cancer and other serious diseases. BioNTech leverages a wide range of computational discovery tools and therapeutic approaches to accelerate the development of new biopharmaceuticals. Its diversified portfolio of oncology product candidates—aimed at addressing the full spectrum of cancer care—includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted treatments such as antibody-drug conjugates (ADCs) and cutting-edge chimeric antigen receptor (CAR) T cell therapies. Building on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for various infectious diseases alongside its diverse oncology pipeline. BioNTech has established extensive partnerships with numerous global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech (a member of the Roche Group), Genmab, MediLink, OncoC4, Pfizer, and Regeneron.
For further information, please visit www.BioNTech.com.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.